

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human IL-17E in direct ELISAs and Western blots. Shows 100% cross-reactivity with recombinant mouse IL-17E and no cross-reactivity with recombinant human (rh) IL-17, rhIL-17B, rhIL-17C, or rhIL-17F.
Source	Monoclonal Mouse IgG ₁ Clone # 182203
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human IL-17E Tyr33-Gly177 Accession # Q9H293
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the [Technical Information](#) section on our website.

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human IL-17E/IL-25 (Catalog # 1258-IL)
Intracellular Staining by Flow Cytometry	2.5 µg/10 ⁶ cells	See Below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
ELISA	This antibody functions as an ELISA capture antibody when paired with Goat Anti-Human IL-17E/IL-25 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1258). <i>This product is intended for assay development on various assay platforms requiring antibody pairs.</i>	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

The Interleukin 17 (IL-17) family proteins, comprising six members (IL-17, and IL-17B through IL-17F), are secreted, structurally related proteins that share a conserved cysteine-knot fold near the C-terminus, but have considerable sequence divergence at the N-terminus. With the exception of IL-17B, which exists as a non-covalently linked dimer, all IL-17 family members are disulfide-linked dimers. IL-17 family proteins are pro-inflammatory cytokines that induce local cytokine production and are involved in the regulation of immune functions (1, 2).

Human IL-17E cDNA encodes a 177 amino acid (aa) residues precursor protein with a putative 32 aa signal peptide (3). A second isoform of human IL-17E encoding a 161 aa precursor protein also exists (4). The two isoforms differ in their signal peptide sequences. Mature human IL-17E shares 76% aa sequence identity with mature mouse IL-17E. Human IL-17E also shares from 25-36% aa sequence identity with the other human IL-17 family members. IL-17E expression was detected at very low levels by PCR in various peripheral tissues including brain, kidney, lung, prostate, testis, adrenal gland, spinal cord, and trachea (3). IL-17E binds and activates IL-17 B Receptor (IL-17B R) (alternatively known as IL-17 Rh1, IL-17E R, and EVI27) (3), which is expressed in kidney and liver, and at lower levels in brain, testis, and other endocrine tissues. The expression of IL-17B R is up regulated under inflammatory conditions. Ligation of IL-17E to IL-17 RB induces activation of nuclear factor kappa-B and stimulates the production of the pro-inflammatory cytokine IL-8 (3). IL-17 has also been found to promote the expression of the prototypical Th2 genes (4, 5).

References:

1. Aggarwal, S. and A.L. Gurney (2002) *J. Leukoc. Biol.* **71**:1.
2. Moseley, T.A. *et al.* (2003) *Cytokine & Growth Factor Rev.* **14**:155.
3. Lee, J. *et al.* (2001) *J. Biol. Chem.* **276**:1660.
4. Hurst, S.D. *et al.* (2002) *J. Immunol.* **169**:443.
5. Pan, G. *et al.* (2001) *J. Immunol.* **167**:6569.